Transfusion medicine service policies for recombinant factor VIIa administration

Keyphrases

• Recombinant Activated Factor VII (rFVIIa) 100%
• Medicine Services 100%
• Transfusion Medicine 100%
• Recombinant FVIIa 100%
• Service Policy 100%
• Bleeding 40%
• Thrombin Generation 40%
• Clinical Trials 20%
• Clinical Application 20%
• Transfusion 20%
• Safety Efficacy 20%
• Pharmacological Dose 20%
• Hemostasis 20%
• Thrombocytopenia 20%
• Randomized Clinical Trial 20%
• Pharmaceutics 20%
• Activated Platelets 20%
• Recent Trends 20%
• Factor VIII (FVIII) 20%
• Hemophilia Patients 20%
• Uncontrolled Bleeding 20%
• Safety Cost 20%
• Acquired Hemophilia A 20%
• Platelet Defects 20%
• Impaired Liver Function 20%
• Profuse Bleeding 20%

Medicine and Dentistry

• Bleeding 100%
• Thrombin 100%
• Transfusion Medicine 100%
• Recombinant Blood Clotting Factor 7a 100%
• Health Care Cost 50%
• Clinical Trial 50%
• Blood Stasis 50%
• Thrombocytopenia 50%
• Haemophilia A 50%
• Liver Function 50%
• Thrombocyte Activation 50%
• Patient with Hemophilia 50%
• Thrombocyte Anomaly 50%
• Randomized Clinical Trials 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Bleeding 100%
• Thrombin 100%
• Recombinant Blood Clotting Factor 7a 100%
• Haemophilia A 100%
• Clinical Trial 50%
• Thrombocytopenia 50%
• Randomized Clinical Trial 50%
• Blood Stasis 50%
• Thrombocyte Anomaly 50%